Scientific Program
The primary focus of EVF’s scientific program is on facilitating translational research from discovery to early phase I/II clinical development.
Collaborations with different academic groups
Since its inception, EVF has successfully collaborated with different academic groups and supported the development of a number of HIV vaccine candidates from bench to clinic.
EVF has sponsored or co-sponsored multiple phase I/II HIV Vaccine Trials in Europe and Africa, in both prophylactic and therapeutic settings. These trials are funded and co-funded by European Commission 5th and 7th Framework Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), HIV Vaccine Trial Network(HVTN)/National Institute of Health (NIH) and European and Developing Countries Clinical Trials Partnership (EDCTP).
More recently, EVF is expanding its portfolio to other infectious disease areas through providing scientific project management support to large research consortia with the focus on facilitating the development from bench to clinic. To this end, EVF engages a pool of experts from manufacturing, to regulatory to clinical trials.
Bench to Clinic
EVF has successfully supported the development of a number of HIV vaccine candidates from bench to clinic. These include:
- A DNA based vaccine (DNA-HIV-PT123), designed by University of Regensburg, Germany, is now under evaluation in a phase IIB trial in Sub-Saharan Africa (PrEPVACC)
- Poxvirus-based vaccine candidate, in particular NYVAC. NYVAC is a highly attenuated vaccinia virus strain and has been used as a vector not just for HIV/AIDS vaccines but also for vaccines against other infectious diseases.
- DNA launched replicon RNA vaccine (DREP-HIV-1), designed by Karolinska Institute, Sweden, is now under Phase I clinical trial evaluation.
The development of DNA, NYVAC and DREP, has been funded by European Commission framework programs and the Collaboration for AIDS Vaccine Discovery (CAVD) of the Bill and Melinda Gates Foundation (BMGF).
In addition, EVF has also provided support to other research groups in product development activities, such as the HIV SOSIP trimer vaccines in EHVA, and the COBRA flu vaccine in INCENTIVE.
HIV Vaccine Trials
EVF has sponsored or co-sponsored multiple phase I/II clinical trials in Europe and Africa, in both prophylactic and therapeutic settings.
These trials are funded and co-funded by European Commission 5th and 7th Framework and Horizon 2020 Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), HIV Vaccine Trial Network (HVTN)/National Institute of Health (NIH) and European and Developing Countries Clinical Trials Partnership (EDCTP).
Non-HIV Research Projects
Building on the experience it has gained in the HIV vaccine field, EVF has established collaborations in other infectious disease areas through providing scientific project management support focusing on facilitating the development from bench to clinic.